Exam 2- 8/9/10 Flashcards
(68 cards)
performance status
0-health, 4- bed bound. helps determine if patient should be receiving chemo
neurotransmitters in Emesis
5HT3, D2, NK1
also H1 and M
acute emesis
0-24 hours of chemo
delayed emesis
24 hours- 5 days after chemo
anticipatory emesis
learned response to chemo
breakthrough emesis
nausea or vomiting through prophylaxis
emesis risk factors
intrinsic emetogenecity of chemo, combo therapy, dose, rate of administration, younger patients, women more than men, heavy alcohol associated with REDUCED risk
antiemetic agents: lower therapeutic index
metoclopramide, phenothiazine derivatives, butyripenones, canabinoids, BZD
antiemetic agents: highest therapeutic index
corticosteroids, 5HT3 RA, NK1/substrate P antagonist, olanzapine
metoclopramide MOA
- block DA receptors at the CTZ
- prokinetic effect by increasing gut motility
- 5HT receptor antagonist at higher doses
metoclopramide ADR
diarrhea, EPS, sedation
phenothiazine MOA
block DA receptors at CTZ
- prochloperazine, promethazine
phenothiazine ADRs
sedation, restlessness, hypotension, EPS
butyrophenones MOA
- block DA receptors
- more potent antiDA action in the peripheral NS than phenothiazines
- haloperidol, droperidol
butyrophenones ADRs
sedation, hypotension, EPS (less)
canabinoids MOA
unknown
- dronabinol, nabilone
canibinoids ADRs
sedation, euphoria, hypotension, hallucinations, dry mouth, disorientation
benzodiazepine MOA
- antegrade amnesia- prevents short term memory
- decreases anxiety
- lorazepam
benzo ADRs
amnesia, sedation, hypotension
corticosteroids MOA
- PG blocking
- changes in cellular permeability
- dexamethasone, methylprednisolone
corticosteroid ADRs
- minimal with short duration
- euphoria, anxiety, insomnia, fluid retention, hyperglycemia, GI upset, demargination
5HT3 receptor antagonists MOA
- central and peripheral antagonism
- dolasetron, granisetron, ondansetron: short acting
palnosetron (aloxi): longer T1/2
5HT3 RA ADRS
HA, transient transaminase elevations, constipation
palonosetron
(Aloxi)
- T1/2 40 hours
- indicated for prevention of N/V due to moderate and highly emetogenic chemo
- acute and delayed
- should not repeat dose within 7 days
- Ha, constipation, prolonged QT interval